Roivant’s story looks exciting on the surface, but its biggest upside depends on a legal fight and a drug area that’s getting crowded fast. The bigger worry is that after selling a key asset, the company now has to prove it can turn a large cash pile into new winners without the usual “holding company” drag.Read more
Roivant’s next few clinical trial results and possible new drug deals could reshape its outlook, especially as it focuses on fewer, higher-value programs. But competition from entrenched treatments and a cloud of legal uncertainty mean the path to stronger profits may be bumpier than it looks.Read more
Roivant Sciences is nearing a string of important trial results and potential launches in autoimmune diseases, which could turn its research pipeline into real medicines and a much larger business. A big cash buffer gives it time to execute, but the story hinges on trial success and holding its ground against fast-moving rivals.Read more
Roivant Sciences has a crowded lineup of autoimmune and rare-disease drug candidates, and its next wave of launches could look very different depending on how quickly doctors and insurers embrace them. The catch is that rivals, pricing pressure, and complex trials could slow the payoff, even with a strong cash cushion and promising late-stage results.Read more
No trending discussion available.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
